If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSage Group Regulatory News (SGE)

Share Price Information for Sage Group (SGE)

Share Price is delayed by 15 minutes
Get Live Data
837.00    -2.00 (-0.24%)
Bid:
836.60
Ask:
837.00
Spread: 0.40 (0.048%)
Market Cap: £7.51b
SGE Live PriceLast checked at - London Stock Exchange

Intraday Sage Group Share Chart

Stabilisation Notice

1 Feb 2022 10:26

RNS Number : 3215A
J.P. Morgan Securities PLC.
01 February 2022
 

1st of February 2022

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

The Sage Group plc

Pre-stabilisation Period Announcement

J.P. Morgan Securities plc, (contact: Marc Lewell +33 1 40 15 44 39) hereby gives notice, as Stabilisation Coordinator, that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation EU/xxx/2016 under the Market Abuse Regulation (EU/596/2016).

The securities:

Issuer:

The Sage Group plc

Guarantor (if any):

Sage Treasury Company Limited

Aggregate nominal amount:

GBP bmk

Description:

GBP 12-year Senior, Unsecured, RegS Bearer, NGN, TEFRA D rules apply (no communications with or into the U.S.)

Listing: London Stock Exchange

Offer price:

TBD

Other offer terms:

Denoms: £100k + 1k

Stabilisation:

Stabilisation Manager(s):

J.P. Morgan Securities plc (Stabilisation coordinator)

NatWest Markets (Stabilisation Manager(s))

HSBC ( (Stabilisation Manager(s))

BofA ( (Stabilisation Manager(s))

 

Stabilisation period expected to start on:

1st February 2022

Stabilisation period expected to end no later than:

1st March 2022

Existence, maximum size and conditions of use of overallotment facility:

The Stabilisation Manager(s) may over-allot the securities in an amount not exceeding 5% of the aggregate nominal amount stated above.

Stabilisation trading venue:

Over the counter, TBC

 

In connection with the offer of the above securities, the Stabilising Manager(s), or persons acting on behalf of the Stabilising Manager(s) may over-allot the securities, provided that the aggregate principal amount of the securities allotted does not exceed 105 percent of the aggregate principal amount of the securities, or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time, but it must end no later than the earlier of 30 days after the issue date of the securities and 60 days after the date of allotment of the securities.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that in that Member State

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAEAEAFEAAAEFA
Date   Source Headline
27th Jul 20237:00 amRNSTrading update for nine months ended 30 June 2023
30th Jun 20232:40 pmRNSTotal Voting Rights
30th Jun 20239:48 amRNSDirector/PDMR Shareholding
27th Jun 20235:16 pmRNSDirector/PDMR Shareholding
21st Jun 20239:00 amRNSDirector/PDMR Shareholding
6th Jun 202312:02 pmRNSBlock listing Interim Review
31st May 20234:55 pmRNSHolding(s) in Company
31st May 20234:50 pmRNSTotal Voting Rights
30th May 202310:10 amRNSDirector/PDMR Shareholding
19th May 20234:58 pmRNSDirector/PDMR Shareholding
19th May 20234:45 pmRNSHolding(s) in Company
17th May 20237:00 amRNSResults for the six months to 31 March 2023
28th Apr 20233:30 pmRNSTotal Voting Rights
31st Mar 20232:11 pmRNSDirector/PDMR Shareholding
31st Mar 202312:40 pmRNSTotal Voting Rights
27th Mar 20231:40 pmRNSDirector/PDMR Shareholding
6th Mar 20234:42 pmRNSHolding(s) in Company
28th Feb 20231:50 pmRNSTotal Voting Rights
17th Feb 20235:22 pmRNSDirector/PDMR Shareholding
17th Feb 20235:02 pmRNSDirector/PDMR Shareholding
14th Feb 20233:59 pmRNSDirector/PDMR Shareholding
13th Feb 20236:16 pmRNSPublication of Final Terms
9th Feb 20239:32 amRNSDirector/PDMR Shareholding
7th Feb 20239:46 amRNSDirector/PDMR Shareholding
3rd Feb 202312:14 pmRNSDirector Declaration
2nd Feb 20233:31 pmRNSResult of AGM
2nd Feb 20239:57 amRNSDirector Declaration
31st Jan 20233:35 pmRNSSage: Publication of Base Prospectus
31st Jan 20233:00 pmRNSTotal Voting Rights
23rd Jan 20234:58 pmRNSDirector/PDMR Shareholding
19th Jan 20237:00 amRNSTrading Update for the 3 months ended 31 Dec 2022
30th Dec 202211:15 amRNSTotal Voting Rights
15th Dec 202211:21 amRNSDirector/PDMR Shareholding
8th Dec 20225:40 pmRNSDirector/PDMR Shareholding
8th Dec 20227:00 amRNSUpdate on financial reporting
7th Dec 20226:00 pmRNSDirector/PDMR Shareholding
7th Dec 202210:12 amRNSNotice of AGM
6th Dec 20226:13 pmRNSDirector/PDMR Shareholding
6th Dec 20225:23 pmRNSDirector/PDMR Shareholding
6th Dec 202210:25 amRNSBlock listing Interim Review
1st Dec 202211:03 amRNSAnnual Financial Report
30th Nov 20222:00 pmRNSTotal Voting Rights
24th Nov 202210:00 amRNSNon-executive Director Appointment
18th Nov 20229:13 amRNSDirector/PDMR Shareholding
16th Nov 20227:00 amRNSResults for the year ended 30 September 2022
15th Nov 20227:00 amRNSNon-executive Director Appointment
31st Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202211:45 amRNSTotal Voting Rights
20th Sep 20227:00 amRNSInvestor and Analyst Event
31st Aug 20223:44 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.